WORLD HEART FEDERATION (WHF) COVID-19 and Cardiovascular Disease Survey

  • STATUS
    Recruiting
  • participants needed
    5200
  • sponsor
    Public Health Foundation of India
Send
Updated on 5 August 2020
See if I qualify
cardiovascular disease
cardiovascular complications
covid-19
cardiovascular complication

Summary

A global study for a better understanding of the cardiovascular conditions that increase the risk of developing severe COVID-19, and a better characterization of cardiovascular complications in hospitalized patients with COVID-19.

Description

COVID-19 may be cardiotropic in a subset of patients. Both acute and pre-existing CVD impact outcomes unfavorably. It is possible that one common CVD treatment, medications that impact ACE-2 function, may impact outcomes either favorably or unfavorably.

However, studies so far have, perforce, been conducted with important limitations (e.g. small numbers, limited geographical representation, lack of data standardization for risk factors and outcomes, limited measurement, lack of appropriate adjustment for important confounders, and missing data). Considering the high global prevalence of CVD and its risk factors (e.g. hypertension and diabetes) and the suggested link with COVID19 it is urgent to initiate more robust studies to clarify the many issues early reports have engendered. So that investigators will conduct a global study for a better understanding of the cardiovascular conditions that increase the risk of developing severe COVID-19, and a better characterization of cardiovascular complications in hospitalized patients with COVID-19.

Details
Condition Cardiovascular Disease, Covid 19
Age 18years - 100years
Clinical Study IdentifierNCT04475471
SponsorPublic Health Foundation of India
Last Modified on5 August 2020

Eligibility

 Yes No Not Sure

Inclusion Criteria

All adults (as locally defined) with confirmed COVID-19 infection who are hospitalized are eligible

Exclusion Criteria

Patients for whom investigators are unable to obtain informed consent will be excluded
Patients who are unlikely to stay in the recruiting centre for 30 days (i.e. likely to be transferred)
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

cardiovascular disease
cardiovascular complications
covid-19
cardiovascular complication

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.